Fudan University
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1905-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.fudan.edu.cn
Cetuximab Re-challenge for Colorectal Cancer Liver Metastasis
Phase 3
Not yet recruiting
- Conditions
- Liver MetastasesColorectal CancerCetuximab
- Interventions
- Drug: CetuximabDrug: Chemotherapy
- First Posted Date
- 2020-08-12
- Last Posted Date
- 2020-08-12
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 50
- Registration Number
- NCT04509635
Anti-EGFR Therapy With IMRT Concurrent Chemoradiotherapy in Locally Advanced OPC Resistant to Induction Chemotherapy
Phase 2
- Conditions
- Oropharyngeal Carcinoma
- Interventions
- Drug: Anti-EGFR monoclonal antibody
- First Posted Date
- 2020-08-11
- Last Posted Date
- 2022-04-04
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 52
- Registration Number
- NCT04508829
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer
Phase 2
- Conditions
- Treatment Efficacy
- Interventions
- Drug: HX008，NiraparibDrug: HX008，Niraparib，TrastuzumabDrug: HX008，Niraparib，Pyrrolitinib
- First Posted Date
- 2020-08-11
- Last Posted Date
- 2022-06-30
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 37
- Registration Number
- NCT04508803
- Locations
- 🇨🇳
Fudan University Shanghai Cancer center, Shanghai, China
Anti-EGFR Therapy Plus IMRT Concurrent Chemoradiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy
Phase 2
Completed
- Conditions
- Nasopharyngeal Carcinoma
- Interventions
- First Posted Date
- 2020-08-11
- Last Posted Date
- 2022-04-04
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 45
- Registration Number
- NCT04508816
- Locations
- 🇨🇳
Xiaoshen Wang, Shanghai, China
A Study of Radiotherapy Combined With Raltitrexed and Irinotecan in Metastatic or Locally Recurrent Colorectal Cancer
Phase 2
- Conditions
- Recurrent Colorectal Cancer
- Interventions
- Combination Product: Radiotherapy Combined With Raltitrexed and Irinotecan
- First Posted Date
- 2020-08-05
- Last Posted Date
- 2020-08-05
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 30
- Registration Number
- NCT04499586
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Efficacy and Safety of Camrelizumab Combined With Nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer
Phase 2
- Conditions
- Metastatic Pancreatic Cancer
- Interventions
- First Posted Date
- 2020-08-04
- Last Posted Date
- 2020-08-04
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 117
- Registration Number
- NCT04498689
- Locations
- 🇨🇳
Department of Pancreatic and Hepatobiliary Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University, Shanghai, Shanghai, China
Prospective Observation of Failure Patterns in NSCLC Treated With ICIs
Not yet recruiting
- Conditions
- NSCLC, RecurrentNSCLC Stage IV
- First Posted Date
- 2020-07-30
- Last Posted Date
- 2020-07-31
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 320
- Registration Number
- NCT04492969
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Megestrol Acetate Plus Rosuvastatin in Young Women With Atypical Endometrial Hyperplasia
Phase 2
Completed
- Conditions
- Atypical Endometrial Hyperplasia
- Interventions
- First Posted Date
- 2020-07-29
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 36
- Registration Number
- NCT04491682
- Locations
- 🇨🇳
Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China
Megestrol Acetate Plus Rosuvastatin in Young Women With Early Endometrial Carcinoma
Phase 2
Recruiting
- Conditions
- Endometrial Carcinoma Stage I
- Interventions
- First Posted Date
- 2020-07-29
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 48
- Registration Number
- NCT04491643
- Locations
- 🇨🇳
Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China
Maintenance Treatment of Toripalimab(JS001) in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma
Phase 2
- Conditions
- Mucosal Melanoma
- Interventions
- Drug: ToripalimabDrug: chemotherapy in combination with Endostar
- First Posted Date
- 2020-07-15
- Last Posted Date
- 2020-07-15
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 31
- Registration Number
- NCT04472806
- Locations
- 🇨🇳
Zhiguo Luo, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath